A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06588855 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderately to Severely Active Ulcerative Colitis

Interventions

DRUG: Afimkibart
DRUG: Placebo

Sponsor

Hoffmann-La Roche